Table 2.
Rates of acute and late adverse events among prostate cancer patients (n = 110)
|
Grade |
Acute |
Late |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | |||
| GI |
Total |
103 |
7 |
0 |
0 |
102 |
8 |
0 |
0 |
|
| 93.6% |
6.4% |
0% |
0% |
92.7% |
7.3% |
0% |
0% |
|||
| |
Rectal mucositis/pain |
|
7 |
|
|
|
|
|
|
|
| |
Rectal bleeding |
|
|
|
|
|
8 |
|
|
|
| GU |
Total |
55 |
44 |
1 |
0 |
90 |
17 |
3 |
0 |
|
| 50.0% |
40.0% |
0.9% |
0% |
81.8% |
15.5% |
2.7% |
0% |
|||
| Frequency |
|
30 |
1 |
|
|
|
|
|
||
| Cystitis noninfective |
|
27 |
|
|
|
11 |
1 |
|
||
| Retention/obstruction |
|
12 |
|
|
|
|
1 |
|
||
| Urgency |
|
14 |
1 |
|
|
7 |
1 |
|
||
| Urethral tract pain | 12 | |||||||||
GI, gastrointestinal; GU, genitourinary. Acute (AE): originating within 90 days from the completion of radiation therapy. Late (AE): appearing more than 90 days from the completion of radiation therapy.